Funabashi, Japan

Shingo Owada



Average Co-Inventor Count = 8.2

ph-index = 3

Forward Citations = 30(Granted Patents)


Company Filing History:


Years Active: 2008-2013

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Shingo Owada: Innovator in Thrombopoietin Receptor Activators

Introduction

Shingo Owada is a prominent inventor based in Funabashi, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of thrombopoietin receptor activators. With a total of 6 patents to his name, Owada's work is recognized for its potential impact on therapeutic applications.

Latest Patents

Among his latest patents, Owada has developed innovative compounds such as 3-ethylidenehydrazino substituted heterocyclic compounds. These compounds serve as thrombopoietin receptor activators and are represented by complex chemical formulas that detail their structural components. Another notable patent involves heterocyclic compounds that also act as thrombopoietin receptor activators, showcasing his expertise in creating novel pharmaceutical agents.

Career Highlights

Shingo Owada is currently employed at Nissan Chemical Industries Limited, where he continues to push the boundaries of chemical innovation. His work has not only contributed to the company's portfolio but has also advanced the field of drug development.

Collaborations

Owada collaborates with esteemed colleagues such as Kazufumi Yanagihara and Norihisa Ishiwata. These partnerships enhance the research environment and foster the exchange of ideas, leading to groundbreaking advancements in their respective fields.

Conclusion

Shingo Owada's contributions to the field of medicinal chemistry, particularly in thrombopoietin receptor activators, highlight his role as a key innovator. His ongoing work at Nissan Chemical Industries Limited and collaborations with fellow researchers position him as a significant figure in the landscape of pharmaceutical development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…